Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Ann E. Weber

Scott D. Edmondson

Jinyou Xu

Dooseop Kim

Malcolm Maccoss

Michael H. Fisher

Emma R. Parmee

Emma R Parmee

Ann E Weber

Songnian Lin

Ronald M Kim

Linda Brockunier

Scott D Edmondson

John E Stelmach

Rui Liang

Subharekha Raghavan

Xibin Liao

Christopher Joseph Sinz

Jiang Chang

Jian Guo

Keith Rosauer

Michael H Fisher

Libo Xu

Amy R Bittner

Yusheng Xiong

James R Tata

Hyun O Ok

Edward Metzger

Robert J Mathvink

Teresa Beeson

Qiang Tan

Roman Kats-Kagan

Dong-Ming Shen

Wallace T Ashton

Darby Schmidt

Jiayi Xu

Fengqi Zhang

Sheryl Davis Debenham

Elizabeth M Naylor

Anthony Mastracchio

Cangming Yang

Sunita V Dewnani

Ashley Rouse Lins

Elizabeth Ashley Rouse

Christian P Stevenson

Charles G Caldwell

Sherman Tim Waddell

Kevin Tyler Chapman

Cameron James Smith

Shouwu Miao

Yi-Heng Chen

Brian T Campbell

Joseph Leslie Duffy

Hong Li

Thomas L Shih

Qinghong Fu

Joie Garfunkle

Rui Zhang

Alan Whitehead

Olga Ornoski

Jonathan A Groeper

Xiaoqing Han

John W Mirc

George Scott Tria

Olga A Ziouzina

Michael Fisher

Samuel Tolman

Keith G Rosauer

Olga A Ornoski

Darby Rye Schmidt

J W Mirc

Linda L Brockunier

Glucagon receptor antagonist compounds are disclosed which are of long duration of action. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use

Novel pyridine-2-carboxamide derivatives of formula I and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are effective as glucokinase activating agents. Pharmaceutical compositions and methods of treatment are also included. The present invention relates to novel pyridine-2-carboxamide derivatives and salts thereof which are effective as glucokinase activating agents. Moreover, it relates to compositions containing such compounds, and methods of treatment. 

2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment

Novel pyridine-2-carboxamide derivatives of formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are effective as glucokinase activating agents. Pharmaceutical compositions and methods of treatment are also included. 

Glucokinase activator compounds, compositions containing such compounds, and methods of treatment

A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate ('cGMP') and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof. 

Soluble guanylate cyclase activators

Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Compounds of Formula I are capable of modulating the body's production of cyclic guanosine monophosphate ('cGMP') and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the Formula I. 

This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

A compound having the structure useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, angina pectoris, thromboses, restenoses, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver in a human or animal patient.

Glucagon receptor antagonist compounds

The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of type 2 diabetes

Glucagon receptor antagonist compounds of formula I are disclosed: The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type (2) diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Substituted aryl and heteroaryl derivatives are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use

Growing community of inventors

Scotch Plains, NJ, United States of America

Emma R Parmee